HMTXF
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $0 | -$816,604 |
| 2025 Q4 | -0.01 | $0 | -$1M |
| 2025 Q3 | -0.00 | $0 | -$2M |
| 2025 Q2 | -0.00 | $0 | -$801,212 |
| 2025 Q1 | -0.01 | $0 | $337,466 |
| 2024 Q4 | -0.03 | $0 | -$2M |
| 2024 Q3 | -0.01 | $0 | -$40,425 |
| 2024 Q2 | -0.01 | $0 | $68,683 |